TaperMeds — Deprescribing Software

Savella Tapering Guide

milnacipran

SNRIFDA 2009
Try TaperMeds

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.

Overview

Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved in the US for fibromyalgia management. It has a roughly 3:1 selectivity for norepinephrine over serotonin reuptake inhibition.

Common Doses

12.5mg, 25mg, 50mg, 100mg

Formulations

Tablets: 12.5mg, 25mg, 50mg, 100mg; Titration pack: 12.5mg and 25mg tablets

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Dual reuptake inhibitor of serotonin and norepinephrine with preferential activity at the norepinephrine transporter (NET > SERT, approximately 3:1 ratio).

Taper Notes

SNRI approved for fibromyalgia (not depression in the US). Short half-life (6–8 hours) requires BID dosing and produces a discontinuation syndrome similar to other SNRIs on abrupt cessation. Taper gradually with proportional reductions.

Maudsley Deprescribing Guidance

Reduce dose gradually over at least 1–2 weeks; transition to proportional ~10% reductions at lower doses. Short half-life means withdrawal symptoms can emerge within 24 hours of a missed dose — emphasize dosing consistency.

Common Withdrawal Symptoms

headachenauseadizzinessirritabilityinsomniaparesthesiaanxiety

Interactions & Safety

Drug Interactions

  • MAOIs — contraindicated (risk of serotonin syndrome)
  • Serotonergic drugs increase serotonin syndrome risk
  • Epinephrine and norepinephrine — enhanced pressor effects

Food Interactions

  • Food does not significantly affect overall absorption (AUC unchanged)
  • No specific food contraindications

Contraindications

  • MAOIs within 14 days
  • Uncontrolled narrow-angle glaucoma
  • Known hypersensitivity to milnacipran

Toxicity

Serotonin syndrome risk. Hypertension and tachycardia. Hepatotoxicity reported rarely.

Pharmacokinetics

ADME Profile

Absorption

Well absorbed (85–90% bioavailability). Tmax ~2–4 hours. Food does not affect AUC but delays Tmax.

Distribution

~400 L

Metabolism

Hepatic — primarily conjugation (glucuronidation), not significantly CYP-mediated. Active desethyl metabolite.

Elimination

Renal (55% unchanged, 24% as glucuronide conjugate).

Protein Binding

13%

Clearance

~60 L/hr

Build Savella taper plans in minutes

TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.

Try TaperMeds

Other Medication Profiles

Book a Free Demo